Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
3.7
4.7
Journals
Biomedicines
Special Issues
Oncolytic Viruses and Combinatorial Immunotherapy for Cancer
share announcement

Oncolytic Viruses and Combinatorial Immunotherapy for Cancer

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Immunology and Immunotherapy".

Deadline for manuscript submissions: 30 May 2024 | Viewed by 1786

Special Issue Editors

Dr. Zong Sheng Guo

E-Mail Website
Guest Editor
Department of Immunology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA
Interests: oncolytic virus; poxviruses; cancer immunotherapy; cancer immunology; oncoimmunology; molecular targeted therapy; combinatorial therapy for cancer
Special Issues, Collections and Topics in MDPI journals
Dr. Michael H. Lehmann

E-Mail Website
Guest Editor
Institute for Infectious Diseases and Zoonoses, Ludwig-Maximilians-Universität München, 85764 Oberschleißheim, Germany
Interests: cell signaling; cell migration; cytokine gene expression; HIV; poxviruses; vaccines; viral vectors; virus–host interactions
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Oncolytic viruses (OVs) are developed as tools for novel cancer therapies. In recent years, investigators have started to realize that the indirect antitumor activity of viruses beyond direct oncolysis is a vital contributor to therapeutic efficacy. OV-induced antitumor immunity plays an important, sometimes essential, role in OV-mediated therapeutics for cancer.

OVs modulate the tumor microenvironment to favor antitumor immunity. Their ability to turn cold tumors immunologically hot is a unique property that makes OVs highly useful agents in combinatorial approaches for cancer immunotherapy.

We cordially invite authors in the field to submit original research or review articles pertaining to this important and fast-advancing field of biomedicine.

The submission of articles addressing (i) the mechanisms of action of OVs, (ii) genetic modifications of OVs for improving their efficacy and safety, (ii) the delivery of OVs, (iv) host responses to OVs and (v) studies with combinatorial approaches is strongly encouraged.

Dr. Zong Sheng Guo
Dr. Michael H. Lehmann
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • oncolytic virus
  • antitumor immunity
  • cold tumor
  • tumor antigen
  • cancer vaccine
  • immunotherapy
  • combinatorial therapy
  • immune checkpoint blockade

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

16 pages, 266 KiB  
Review
Individualized Multimodal Immunotherapy (IMI): Scientific Rationale and Clinical Experience from a Single Institution
by Volker Schirrmacher, Stefaan Van Gool and Wilfried Stuecker
Biomedicines 2024, 12(4), 754; https://0-doi-org.brum.beds.ac.uk/10.3390/biomedicines12040754 - 28 Mar 2024
Viewed by 1540
Abstract
Oncolytic viruses and combinatorial immunotherapy for cancer (this Special Issue) are both part of cancer treatment at IOZK. This review focusses on an individual multimodal cancer immunotherapy concept developed by IOZK, Cologne, Germany. The scientific rationale for employing three main components is explained: [...] Read more.
Oncolytic viruses and combinatorial immunotherapy for cancer (this Special Issue) are both part of cancer treatment at IOZK. This review focusses on an individual multimodal cancer immunotherapy concept developed by IOZK, Cologne, Germany. The scientific rationale for employing three main components is explained: (i) oncolytic Newcastle disease virus, (ii) modulated electrohyperthermia and (iii) individual tumor antigen and oncolytic virus modified dendritic cell vaccine (IO-VACR). The strategy involves repeated cancer-immunity cycles evoked in cancer patients by systemic oncolytic virus exposure plus hyperthermia pretreatment to induce immunogenic cell death followed by intradermal IO-VACR vaccination. As an example of the experience at IOZK, we present the latest results from combining the immunotherapy with standard treatment of patients suffering from glioblastoma multiforme. The promising clinical results in terms of overall survival benefit of additional individualized multimodal immunotherapy are presented. The cancer-immunity cycle, as introduced 10 years ago, describes key important steps occurring locally at the sites of both tumor and draining lymph nodes. This view is extended here towards systemic events occuring in blood where immunogenic cell death-induced tumor antigens are transported into the bone marrow. For 20 years it has been known that bone marrow is an antigen-responsive organ in which dendritic cells present tumor antigens to T cells leading to immunological synapse formation, tumor antigen-specific T cell activation and memory T cell formation. Bone marrow is known to be the most prominent source of de novo cellular generation in the body and to play an important role for the storage and maintenance of immunological memory. Its systemic activation is recommended to augment cancer-immunity cycles. Full article
(This article belongs to the Special Issue Oncolytic Viruses and Combinatorial Immunotherapy for Cancer)
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop